Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.
Transcatheter aortic valve implantation is a promising next-gen technology for common conditions like aortic stenosis. Irvine-based JenaValve Technology just added another $26.5 million to its Series C round, bringing the devicemaker to nearly $100 million for the round for its TAVI prosthetic valve.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medtronic’s (NYSE:MDT) legal battle with Edwards Lifesciences over patent infringement and its transcatheter aortic valve products has been going on for years and last week a federal appeals court affirmed a lower court’s ruling in Edwards’ favor allowing that Medtronic had, in fact, willfully infringed on a single Edwards’ patent. It asked Medtronic to pay damages, […]
St. Jude Medical (NYSE:STJ) announced Monday that it has received CE Mark for its Portico transcatheter aortic valve system for patients who are deemed too sick to undergo open heart surgery to replace diseased heart valves. The medical device manufacturer has received clearance for the 23 mm Portico TAVI valve and St. Jude Medical describes […]